Wang Jingjing, Li Ruijuan, Zhang Guangsen
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2014 Jun;31(3):714-7.
Mitochondrial adenosine triphosphate (ATP) synthase is the key enzyme of mitochondrial oxidative phosphorylation reaction. The down-regulation of the mitochondrial ATP synthase is a hallmark of most human carcinomas, which is the embodiment of the bioenergetic signature of cancer in the performance of the decreased oxidative phosphorylation and increased aerobic glycolysis. Combining with the bioenergetic signature of cancer, studies showed that mitochondrial ATP synthase and multidrug resistance and adverse prognosis of tumor were closely related. Its mechanisms are related to post-transcriptional regulation of the ATP synthase, the hypermethylation of the ATP synthase gene and the inhibitor peptide of the mitochondrial ATP synthase, called ATP synthase inhibitory factor 1 (IF1). In this review, we stress the biological characteristics of mitochondrial ATP synthase and the relationship between ATP synthase and multidrug resistance and prognosis of Malignant tumor, in order to find a new way for tumor therapy.
线粒体三磷酸腺苷（ATP）合酶是线粒体氧化磷酸化反应的关键酶。线粒体ATP合酶的下调是大多数人类癌症的一个标志，这是癌症生物能量特征在氧化磷酸化减少和有氧糖酵解增加表现中的体现。结合癌症的生物能量特征，研究表明线粒体ATP合酶与肿瘤的多药耐药性和不良预后密切相关。其机制与ATP合酶的转录后调控、ATP合酶基因的高甲基化以及线粒体ATP合酶的抑制肽（称为ATP合酶抑制因子1，IF1）有关。在本综述中，我们强调线粒体ATP合酶的生物学特性以及ATP合酶与恶性肿瘤多药耐药性和预后之间的关系，以便为肿瘤治疗找到新途径。
